At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Dr Mehta discussed practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025, the clinical utility of enfortumab vedotin plus pembrolizumab for select patients with advanced or metastatic urothelial cancer, and differing treatment approaches for patients with lymph node–only vs distant metastases.

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

In today’s episode, we had the pleasure of speaking with J. Thaddeus Beck, MD, FACP, about the FDA approval of pembrolizumab and berahyaluronidase alfa-pmph (subcutaneous pembrolizumab; Keytruda Qlex) for subcutaneous injection in adult and pediatric patients at least 12 years of age with solid tumors for which the intravenous formulation of pembrolizumab (Keytruda) is indicated.

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Drs Chiang and Liu discuss the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Dr Liu discusses the 2 VISION trial of tepotinib for NSCLC harboring MET exon 14 skipping alterations, as well as the importance of biomarker testing.

In today’s episode, we had the pleasure of speaking with Andrew Kuykendall, MD, who gave an overview of the myelofibrosis treatment paradigm. Dr Kuykendall is an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida. In our exclusive interview, Dr Kuykendall discussed the prevalence of patients with myelofibrosis who have mutations in JAK2, CALR, or MPL; the crucial roles of the JAK1, JAK2, and IRAK1 pathways in disease progression; the importance of considering JAK inhibition in eligible patients; and the challenges associated with managing cytopenic myelofibrosis.

In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing resistance.

Dr Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.